Probing gender-specific lipid metabolites and diagnostic biomarkers for lung cancer using Fourier transform ion cyclotron resonance mass spectrometry

Guo, Yumei; Wang, Xianmin; Qiu, Ling; Qin, Xuzhen; Liu, Hui; Wang, Yanying; Li, Fang; Wang, Xiaodong; Chen, Guoqiang; Song, Gaoguang; Li, Fenjie; Guo, Shuai; Li, Zhili

doi:10.1016/j.cca.2012.08.010

Cited by 72 publications

(52 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5). LPC acts as a bioactive mediator in wound healing and inflammation (21), but also has a role in the progression of OVC (22) and lung cancer (23). LPC has many subtypes, and each subtype has a different length of carbon chain.…”

Section: Discussionmentioning

confidence: 99%

Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer

Kim

et al. 2014

Oncology Letters

View full text Add to dashboard Cite

Ovarian cancer (OVC) is one of the most difficult types of cancer to detect in the early stages of its development. There have been numerous attempts to identify a biomarker for OVC; however, an accurate diagnostic marker has yet to be identified. The present study profiled OVC candidate metabolites from the serum to identify potential diagnostic markers for OVC. Data regarding low-mass ions (LMIs) in the serum were obtained using matrix-assisted laser desorption/ionization (MALDI)-time-of-flight analysis. MALDI-mass spectrometry (MS) analysis of each serum sample was repeated six times in order to reduce the likelihood of experimental errors. The intensity of the LMI mass peaks were normalized using total peak area sums. The normalized intensity of LMI was used in principal component analysis-discriminant analysis to differentiate between 142 patients with OVC and 100 healthy control participants. Liquid chromatography-MS/MS was used to identify the selected LMIs. Extracted ion chromatogram analysis was used to measure the relative quantity of candidate metabolites from the LMI mass peak areas. The concentration of common metabolites in the serum was determined using ELISA. The top 20 LMI mass peaks with a weigh factor over 0.05 were selected to distinguish between the patients with OVC and the controls. Among the LMIs, two with 184.05 and 496.30 m/z were identified as L-homocysteic acid (HCA) and lysophosphatidylcholine (LPC) (16:0), respectively. The relative quantity of LPC (16:0) was found to be decreased in the OVC serum (P=0.05), while the quantity of HCA was observed to be significantly higher in the OVC serum (P<0.001). HCA was not detected in 59 cases out of the 63 control participants; however, the majority of the cases of OVC (16/25) exhibited significantly higher quantities of HCA. When the cutoff was 10 nmol/ml, the sensitivity and specificity of HCA were 64.0 and 96.9%, respectively. The level of LPC (16:0) was significantly correlated with tumor grade (P=0.045). HCA and LPC (16:0) showed correlation with stage and tumor histology, but the limited sample size resulted in a lack of statistical significance. The findings of the present study suggest that HCA may have potential to be a biomarker for OVC. The stratified screening including LPC (16:0) did not significantly increase the power for OVC screening; however, the present study showed that profiling LMIs in serum may be useful for identifying candidate metabolites for OVC screening.

show abstract

Section: Discussionmentioning

confidence: 99%

Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer

Kim

et al. 2014

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…In particular, this differential metabolite distribution mainly concerned PL species, such as SM 16:0/1, LPC 18:1, LPC 20:4, LPC 20:3, and LPC 22:6; these lipids were associated with lung cancer progression. Authors concluded that serum LPCs could be applied to lung cancer to differentiate patients and healthy subjects and to detect tumors early [48]. Several other pieces of evidence supported the hypothesis that altered lipid compositions can differentiate normal epithelium from tumor.…”

Section: Lipidomics In Cancer Researchmentioning

confidence: 99%

Advances in Lipidomics for Cancer Biomarkers Discovery

Perrotti

Rosa

Cicalini

et al. 2016

IJMS

155

119

View full text Add to dashboard Cite

Lipids play critical functions in cellular survival, proliferation, interaction and death, since they are involved in chemical-energy storage, cellular signaling, cell membranes, and cell–cell interactions. These cellular processes are strongly related to carcinogenesis pathways, particularly to transformation, progression, and metastasis, suggesting the bioactive lipids are mediators of a number of oncogenic processes. The current review gives a synopsis of a lipidomic approach in tumor characterization; we provide an overview on potential lipid biomarkers in the oncology field and on the principal lipidomic methodologies applied. The novel lipidomic biomarkers are reviewed in an effort to underline their role in diagnosis, in prognostic characterization and in prediction of therapeutic outcomes. A lipidomic investigation through mass spectrometry highlights new insights on molecular mechanisms underlying cancer disease. This new understanding will promote clinical applications in drug discovery and personalized therapy.

show abstract

“…The analysis of PLs in cancer cells, tissues, and biofluids is a novel approach and displays growing interest to develop candidate biomarkers of various cancers. Alterations in PL profiles have been associated with cancer diagnosis and treatment (Wenk, 2005;Hammad et al, 2009;Thomas et al, 2010) and specific lipids might be involved in the onset and evolution of cancer (Xiao et al, 2000;Oremek, Sapoutzis, & Lorenz, 2002;Sutphen et al, 2004;Shimma et al, 2007;Dill et al, 2009Dill et al, , 2010Dill et al, , 2011Kim et al, 2009Kim et al, , 2013Min, Kong, & Moon, 2010Jeong et al, 2011;Kang et al, 2011;Liu, Cooks, & Ouyang, 2011Park et al, 2011;Patterson et al, 2011;Doria et al, 2012;Guo et al, 2012;Ishikawa et al, 2012;Lee et al, 2012;Ide et al, 2013;Kurabe et al, 2013;Liao et al, 2013;Xu et al, 2013;Jones et al, 2014;Mirnezami et al, 2014;Patel et al, 2014). Biomarker detection and evaluation based on MS methods is so far well-established in cancer proteomics, but it also has a potential importance in cancer lipidomics.…”

Section: Pls In Various Cancersmentioning

confidence: 99%

Phospholipids as cancer biomarkers: Mass spectrometry‐based analysis

Bandu

Mok

Kim

2016

Mass Spectrometry Reviews

139

114

View full text Add to dashboard Cite

Lipids, particularly phospholipids (PLs), are key components of cellular membrane. PLs play important and diverse roles in cells such as chemical-energy storage, cellular signaling, cell membranes, and cell-cell interactions in tissues. All these cellular processes are pertinent to cells that undergo transformation, cancer progression, and metastasis. Thus, there is a strong possibility that some classes of PLs are expected to present in cancer cells and tissues in cellular physiology. The mass spectrometric soft-ionization techniques, electrospray ionization (ESI), and matrix-assisted laser desorption/ionization (MALDI) are well-established in the proteomics field, have been used for lipidomic analysis in cancer research. This review focused on the applications of mass spectrometry (MS) mainly on ESI-MS and MALDI-MS in the structural characterization, molecular composition and key roles of various PLs present in cancer cells, tissues, blood, and urine, and on their importance for cancer-related problems as well as challenges for development of novel PL-based biomarkers. The profiling of PLs helps to rationalize their functions in biological systems, and will also provide diagnostic information to elucidate mechanisms behind the control of cancer, diabetes, and neurodegenerative diseases. The investigation of cellular PLs with MS methods suggests new insights on various cancer diseases and clinical applications in the drug discovery and development of biomarkers for various PL-related different cancer diseases. PL profiling in tissues, cells and body fluids also reflect the general condition of the whole organism and can indicate the existence of cancer and other diseases. PL profiling with MS opens new prospects to assess alterations of PLs in cancer, screening specific biomarkers and provide a basis for the development of novel therapeutic strategies. © 2016 Wiley Periodicals, Inc. Mass Spec Rev 37:107-138, 2018.

show abstract

Probing gender-specific lipid metabolites and diagnostic biomarkers for lung cancer using Fourier transform ion cyclotron resonance mass spectrometry

Cited by 72 publications

References 42 publications

Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer

Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer

Advances in Lipidomics for Cancer Biomarkers Discovery

Phospholipids as cancer biomarkers: Mass spectrometry‐based analysis

Contact Info

Product

Resources

About